Olympic Ophthalmics has received 510(k) clearance from the US Food and Drug Administration (FDA) for its next-generation iTEAR100 neurostimulation device.
The neuromodulation device is intended to increase tear production in 30 days in adult patients.
Claimed to facilitate patient access, the connected device will enable communication between patients and eye care providers.
Furthermore, it can help gather data and offers a platform between home and office, thereby optimising dry eye treatment.
It also offers telehealth tools, including the ability to download prescriptions, as well as activation through a mobile phone application.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The iTEAR100 device is claimed to be the only FDA-cleared at-home prescription medical device to boost natural tear production and serve as a bridge between the ophthalmic clinic and patients.
Additionally, the company announced three ongoing trials.
One trial is on patients with newly diagnosed dry eye disease using iTEAR100 as the first treatment. The second is a virtual telehealth trial, where the device is prescribed, monitored and measured by a physician without the patient needing to visit a clinic. The third is a label expansion study to optimise basal tear secretion as against reflex tearing to leverage its on-off and customisable treatment.
Olympic Ophthalmics founder and CEO Michael Gertner said: “After several months of slowed development due to supply chain constraints, we are ready to roll out the iTEAR100 with its associated features at scale, which will facilitate its usage in a telehealth environment.
“We are also excited to finish enrollment of our three Phase IV trials, which will further support our current label for iTEAR100.
“We are also pleased that the uniqueness of the iTEAR100 technology and treatment paradigms are being recognised by patent offices across the world.
“Neurostimulation approaches to Ocular Surface Disease have received FDA approvals and have also earned clinical acceptance by patients and clinicians.”
The company stated that it has been issued or allowed 12 patents regarding the device mechanism and treatment approaches.
Out of the 12 patents, nine are in the US, as well as one each in the EU, Japan and China.